AGEAX
Price
$12.84
Change
-$0.03 (-0.23%)
Updated
Jun 2 closing price
Net Assets
50M
BCLPX
Price
$8.67
Change
-$0.03 (-0.34%)
Updated
Jun 2 closing price
Net Assets
4.78B
Interact to see
Advertisement

AGEAX vs BCLPX

Header iconAGEAX vs BCLPX Comparison
Open Charts AGEAX vs BCLPXBanner chart's image
AGEAX vs BCLPX Comparison Chart in %
View a ticker or compare two or three
VS
AGEAX vs. BCLPX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEAX is a Hold and BCLPX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
BCLPX has more cash in the bank: 4.78B vs. AGEAX (50M). BCLPX pays higher dividends than AGEAX: BCLPX (3.07) vs AGEAX (0.44). AGEAX was incepted earlier than BCLPX: AGEAX (13 years) vs BCLPX (18 years). BCLPX (2.36) is less costly to investors than AGEAX (1.88). AGEAX is a more actively managed with annual turnover of: 195.00 vs. BCLPX (81.00). BCLPX has a lower initial minimum investment than AGEAX: BCLPX (1000) vs AGEAX (2000). AGEAX annual gain was more profitable for investors over the last year : 7.19 vs. BCLPX (3.88). AGEAX return over 5 years is better than : 14.12 vs. BCLPX (6.02).
AGEAXBCLPXAGEAX / BCLPX
Total Expense Ratio1.712.2775%
Annual Report Gross Expense Ratio1.882.3680%
Fund Existence13 years18 years-
Gain YTD1.7391.281136%
Front Load3%N/A-
Min. Initial Investment20001000200%
Min. Initial Investment IRAN/AN/A-
Net Assets50M4.78B1%
Annual Yield % from dividends0.443.0714%
Returns for 1 year7.193.88185%
Returns for 3 years20.9214.83141%
Returns for 5 years14.126.02235%
Returns for 10 years47.6720.60231%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MPB32.870.76
+2.37%
Mid Penn Bancorp
CPRX31.27N/A
N/A
Catalyst Pharmaceuticals
BCDA0.90-0.03
-2.71%
BioCardia Inc.
TEAM109.10-6.85
-5.91%
Atlassian Corp
GALT2.42-0.19
-7.28%
Galectin Therapeutics